MGMahsa Gheitasi

Mahsa Gheitasi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mahsa Gheitasi has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Sepehr Safdel

    Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Abdollah Jafarzadeh

    Department of Immunology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.

    1 shared publication
  • Fatemeh Ayoobi

    Occupational Safety and Health Research Center, NICICO, World Safety Organization and Rafsanjan University of Medical Sciences, Rafsanjan, Iran

    1 shared publication
  • Hossein Khorramdelazad

    Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

    1 shared publication
  • Javad Masoumi

    Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

    1 shared publication
  • Mohammad Hossein Nicknam

    Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran

    1 shared publication

Latest Publications

  • Open Access

    Heart Transplantation: Immunological Challenges Revisited

    by Sara Assadiasl, Sepehr Safdel, Mahsa Gheitasi, Mohammad Hossein Nicknam

    Introduction: Immunologic responses to cardiac allografts initiate before transplantation during brain-dead organ procurement and might persist for years after transplantation, culminating in chronic allograft dysfunction. Despite remarkable advances in post-transplant care and immunosuppressive agents, acute cellular and antibody-mediated rejections as well as chronic allograft vasculopathy significantly affect cardiac allograft and patient survival. Methods: Herein, recent findings of the molecular mechanisms involved in the inflammatory responses before and after heart transplantation, including brain death donor inflammation, acute cellular rejection, antibody-mediated rejection, and chronic allograft dysfunction, have been summarized, along with novel therapeutic approaches for their treatment. Finally, recent developments in prognostic and diagnostic biomarkers for immunological complications have been provided, with an overview of the most promising biomarkers to date. Results and Discussion: Due to the recent developments in the description of molecular mechanisms involved in the immunopathogenesis of cardiac allograft rejection, some immune cells, proinflammatory cytokines, and adhesion molecules have been proposed as therapeutic targets for the prevention or treatment of alloimmune responses. In addition, several molecules derived from graft tissue or immune cells, e.g. natriuretic peptides, cardiac troponins, exosomal products, microRNAs, and donor-derived cell-free DNA, have been suggested as potential biomarkers for the prediction or diagnosis of cardiac transplant rejection. Conclusion: Considering the need to design non-invasive, low-cost tests for early diagnosis of post-transplant complications and convenient follow-up of the cardiac transplant recipients, peripheral blood biomarkers could be appropriate candidates for this purpose.


  • Vaccination with celecoxib-treated dendritic cells improved cellular immune responses in an animal breast cancer model

    by Raziyeh Zandvakili, Pedram Basirjafar, Javad Masoumi, Nahid Zainodini, Zahra Taghipour, Hossein Khorramdelazad, Soheila Yousefi, Tayyebeh Tavakoli, Sepehr Safdel, Mahsa Gheitasi, et al.